CN105380935B - 一种丙戊酸钠药物组合物 - Google Patents
一种丙戊酸钠药物组合物 Download PDFInfo
- Publication number
- CN105380935B CN105380935B CN201410442569.3A CN201410442569A CN105380935B CN 105380935 B CN105380935 B CN 105380935B CN 201410442569 A CN201410442569 A CN 201410442569A CN 105380935 B CN105380935 B CN 105380935B
- Authority
- CN
- China
- Prior art keywords
- sodium
- pharmaceutical composition
- vedproate
- sodium vedproate
- propane diols
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title claims abstract description 69
- 239000011734 sodium Substances 0.000 title claims abstract description 69
- 229910052708 sodium Inorganic materials 0.000 title claims abstract description 69
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims abstract description 37
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims abstract description 37
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 229940113088 dimethylacetamide Drugs 0.000 claims abstract description 21
- WGYFACNYUJGZQO-UHFFFAOYSA-N aminomethanetriol Chemical compound NC(O)(O)O WGYFACNYUJGZQO-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 12
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 12
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 68
- 235000010265 sodium sulphite Nutrition 0.000 claims description 34
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 24
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 230000004087 circulation Effects 0.000 claims description 21
- 239000003182 parenteral nutrition solution Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 abstract description 21
- 239000007924 injection Substances 0.000 abstract description 21
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 22
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 22
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 22
- 230000001954 sterilising effect Effects 0.000 description 20
- 239000012535 impurity Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 239000004471 Glycine Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 10
- 239000008215 water for injection Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 206010015037 epilepsy Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229960000604 valproic acid Drugs 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- 206010034759 Petit mal epilepsy Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000028311 absence seizure Diseases 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940005605 valeric acid Drugs 0.000 description 2
- NLQMSBJFLQPLIJ-UHFFFAOYSA-N (3-methyloxetan-3-yl)methanol Chemical compound OCC1(C)COC1 NLQMSBJFLQPLIJ-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 208000033001 Complex partial seizures Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- -1 dimethylacetamide Amine Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 208000028316 focal seizure Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000004552 water soluble powder Substances 0.000 description 1
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410442569.3A CN105380935B (zh) | 2014-09-03 | 2014-09-03 | 一种丙戊酸钠药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410442569.3A CN105380935B (zh) | 2014-09-03 | 2014-09-03 | 一种丙戊酸钠药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105380935A CN105380935A (zh) | 2016-03-09 |
CN105380935B true CN105380935B (zh) | 2018-04-03 |
Family
ID=55414116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410442569.3A Active CN105380935B (zh) | 2014-09-03 | 2014-09-03 | 一种丙戊酸钠药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105380935B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109580831B (zh) * | 2018-12-28 | 2022-05-13 | 四川健能制药有限公司 | 丙戊酸钠口服溶液有关物质测定方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101524345A (zh) * | 2009-03-13 | 2009-09-09 | 天津南开允公医药科技有限公司 | 一种无需任何赋型剂的药物组合物及其制备工艺 |
CN102079699A (zh) * | 2010-02-11 | 2011-06-01 | 成都科瑞德医药投资有限责任公司 | 丙戊酸钠的新晶型及其制备方法和用途 |
CN103054795A (zh) * | 2012-11-29 | 2013-04-24 | 四川健能制药有限公司 | 丙戊酸钠溶液 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ270438A (en) * | 1995-02-02 | 1996-03-26 | Bernard Charles Sherman | Solid (granular) mixture of valproic acid (di-n-propyl acetic acid) and its sodium salt; pharmaceutical compositions |
WO2008095221A1 (en) * | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of adhd |
-
2014
- 2014-09-03 CN CN201410442569.3A patent/CN105380935B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101524345A (zh) * | 2009-03-13 | 2009-09-09 | 天津南开允公医药科技有限公司 | 一种无需任何赋型剂的药物组合物及其制备工艺 |
CN102079699A (zh) * | 2010-02-11 | 2011-06-01 | 成都科瑞德医药投资有限责任公司 | 丙戊酸钠的新晶型及其制备方法和用途 |
CN103054795A (zh) * | 2012-11-29 | 2013-04-24 | 四川健能制药有限公司 | 丙戊酸钠溶液 |
Non-Patent Citations (1)
Title |
---|
注射用丙戊酸钠(德巴金)在癫痫术后的应用;梁树立等;《临床神经外科杂志》;20041231;第1卷(第1期);第30-32页 * |
Also Published As
Publication number | Publication date |
---|---|
CN105380935A (zh) | 2016-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Determination of clenbuterol in porcine tissues using solid-phase extraction combined with ultrasound-assisted dispersive liquid–liquid microextraction and HPLC–UV detection | |
CN103076409B (zh) | 奥拉西坦及其杂质的分析检测方法 | |
CN104013571A (zh) | 一种奥硝唑注射液及其制备方法 | |
EP3954371A1 (en) | Anti-acetylcholinesterase active composition in caulis mahoniae and screening method therefor and application thereof | |
CN102772409B (zh) | 一种药物组合物 | |
CN106706789B (zh) | 用高效液相色谱法测定盐酸屈他维林注射液中有关物质的方法 | |
CN110398555A (zh) | 一种卡培他滨有关物质的检测方法 | |
Lanjwani et al. | High performance liquid chromatographic determination of platinum in blood and urine samples of cancer patients after administration of cisplatin drug using solvent extraction and N, N′-bis (salicylidene)-1, 2-propanediamine as complexation reagent | |
CN102445500A (zh) | 一种检测注射用益气复脉中的大分子物质的方法 | |
CN105380935B (zh) | 一种丙戊酸钠药物组合物 | |
CN101929985A (zh) | 一种用高效液相色谱法测定阿托伐他汀钙有关物质的方法 | |
CN110441426A (zh) | 一种甲磺酸达比加群酯的检测方法 | |
Kadam et al. | Exploration of mixed hydrotropy strategy in formulation and development of etodolac injection | |
CN105301127A (zh) | 一种利巴韦林药物组合物及其有关物质检测方法 | |
CN106645542A (zh) | 一种测定右旋布洛芬有关物质的方法 | |
CN106525994A (zh) | 一种氨酚曲马多胶囊有关物质的测定方法 | |
CN106918671A (zh) | 测定原料药中n,n-二甲基乙酰胺溶剂残留的方法 | |
CN106932347B (zh) | 一种美洛西林酸及其质量指标检测方法 | |
CN107870211A (zh) | 一种分离测定盐酸帕洛诺司琼的液相色谱方法 | |
CN103816126B (zh) | 一种含有丁溴东莨菪碱的药物组合物 | |
CN103877579B (zh) | 一种含有法莫替丁的药物组合物及其制剂 | |
CN102657646B (zh) | 一种药物组合物及其制剂 | |
Shahe et al. | Compatibility studies between propafenone and selected excipients used in the development of controlled release formulations | |
CN109387574A (zh) | 一种分离分析磷丙泊酚钠有关物质的hplc方法 | |
CN104569172A (zh) | 一种用液相色谱检测苯甲酸阿格列汀片溶出度的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Applicant after: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Address before: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Applicant before: Changchun Haiyue Pharmaceutical Co.,Ltd. |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A sodium valproate drug combination Effective date of registration: 20231226 Granted publication date: 20180403 Pledgee: China Construction Bank Co.,Ltd. Changchun Science and Technology Sub branch Pledgor: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Registration number: Y2023220000149 |